CombinatoRx, Incorporated
245 First Street
Third Floor
Cambridge,
MA 02142
United States - Map
Phone: 617-301-7000
Fax: 617-301-7010
Web Site: http://www.combinatorx.com
| CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The companys products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. The company has a collaboration and licensing agreement with Clinical Data Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. CombinatoRx, Incorporated also has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charleys Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Robert Forrester LL.B., 46
Chief Exec. Officer and Interim Pres |
$
446.00K |
$
0 | Mr. Jason F. Cole Esq., 36
Sr. VP, Sec. and Gen. Counsel |
$
345.00K |
$
0 | Ms. Lynn Baird Ph.D., 61
Consultant |
$
294.00K |
$
0 | Mr. Justin Renz ,
Chief Financial Officer and Sr. VP |
N/A
| N/A | Ms. Gina Nugent ,
VP of Corp. Communications & Investor Relations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
